Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 278

1.

An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.

Tal Y, Yaakobi S, Horovitz-Fried M, Safyon E, Rosental B, Porgador A, Cohen CJ.

Oncotarget. 2014 Nov 15;5(21):10949-58.

2.

The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.

Sun S, Jia Q, Zenova AY, Chafeev M, Zhang Z, Lin S, Kwan R, Grimwood ME, Chowdhury S, Young C, Cohen CJ, Oballa RM.

Bioorg Med Chem Lett. 2014 Sep 15;24(18):4397-401. doi: 10.1016/j.bmcl.2014.08.017. Epub 2014 Aug 14.

PMID:
25176194
3.

High-risk case identification for use in comprehensive complex care management.

Cohen CJ, Flaks-Manov N, Low M, Balicer RD, Shadmi E.

Popul Health Manag. 2015 Feb;18(1):15-22. doi: 10.1089/pop.2014.0011. Epub 2014 Jul 30.

PMID:
25075954
4.

Social values as an independent factor affecting end of life medical decision making.

Cohen CJ, Chen Y, Orbach H, Freier-Dror Y, Auslander G, Breuer GS.

Med Health Care Philos. 2015 Feb;18(1):71-80. doi: 10.1007/s11019-014-9581-x.

PMID:
24965073
5.

Reduction in myocardial infarction incidence: focus on socioeconomic disparities.

Reges O, Leibowitz M, Hoshen M, Rabi Y, Gluzman I, Cohen CJ, Balicer RD.

Int J Cardiol. 2014 Jul 1;174(3):773-4. doi: 10.1016/j.ijcard.2014.04.073. Epub 2014 Apr 15. No abstract available.

PMID:
24794958
6.
7.

Letter to the editor.

Goldberg YP, Cohen CJ, Namdari R, Price N, Cadieux JA, Young C, Sherrington R, Pimstone SN.

Pain. 2014 Apr;155(4):837-8. doi: 10.1016/j.pain.2014.01.003. Epub 2014 Jan 13. No abstract available.

PMID:
24434731
8.

Pneumococcal vaccine targeting strategy for older adults: customized risk profiling.

Balicer RD, Cohen CJ, Leibowitz M, Feldman BS, Brufman I, Roberts C, Hoshen M.

Vaccine. 2014 Feb 12;32(8):990-5. doi: 10.1016/j.vaccine.2013.12.020. Epub 2013 Dec 31.

PMID:
24384054
9.

Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.

Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ.

J Immunol. 2013 Oct 15;191(8):4121-9. doi: 10.4049/jimmunol.1203085. Epub 2013 Sep 11.

10.
11.

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M.

HIV Clin Trials. 2013 May-Jun;14(3):81-91. doi: 10.1310/hct1403-81.

PMID:
23835510
12.

Enhanced antitumor activity mediated by human 4-1BB-engineered T cells.

Daniel-Meshulam I, Horovitz-Fried M, Cohen CJ.

Int J Cancer. 2013 Dec 15;133(12):2903-13. doi: 10.1002/ijc.28320. Epub 2013 Jul 16.

PMID:
23754772
13.

Intellectual disability and space: critical narratives of exclusion.

Gabel SL, Cohen CJ, Kotel K, Pearson H.

Intellect Dev Disabil. 2013 Feb;51(1):74-80. doi: 10.1352/1934-9556-51.01.074.

PMID:
23360410
14.

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.

Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, Rhame F, Stellbrink HJ, Li T, Crauwels H, Rimsky L, Vanveggel S, Williams P, Boven K; ECHO, THRIVE study groups.

AIDS. 2013 Mar 27;27(6):939-50. doi: 10.1097/QAD.0b013e32835cee6e.

PMID:
23211772
15.

Manufacturers' postmarketing safety surveillance of influenza vaccine exposure in pregnancy.

Khromava A, Cohen CJ, Mazur M, Kanesa-thasan N, Crucitti A, Seifert H.

Am J Obstet Gynecol. 2012 Sep;207(3 Suppl):S52-6. doi: 10.1016/j.ajog.2012.06.074. Epub 2012 Jul 9. Review.

PMID:
22920060
16.

How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer.

Daniel-Meshulam I, Ya'akobi S, Ankri C, Cohen CJ.

Front Immunol. 2012 Jul 6;3:186. doi: 10.3389/fimmu.2012.00186. eCollection 2012.

17.

Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity.

Haga-Friedman A, Horovitz-Fried M, Cohen CJ.

J Immunol. 2012 Jun 1;188(11):5538-46. doi: 10.4049/jimmunol.1103020. Epub 2012 Apr 27.

18.

A CCR6 variant strongly associated with rheumatoid arthritis in two populations is not associated with ankylosing spondylitis.

Cohen CJ, Karaderi T, Pointon JJ, Wordsworth BP.

Rheumatol Int. 2013 Sep;33(9):2443-4. doi: 10.1007/s00296-012-2404-6. Epub 2012 Apr 8. No abstract available.

PMID:
22527137
19.

CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy.

Sapoznik S, Ortenberg R, Galore-Haskel G, Kozlovski S, Levy D, Avivi C, Barshack I, Cohen CJ, Besser MJ, Schachter J, Markel G.

Cancer Immunol Immunother. 2012 Oct;61(10):1833-47. Epub 2012 Mar 24.

PMID:
22441657
20.

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.

Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, Supparatpinyo K, Crauwels H, Lefebvre E, Rimsky LT, Vanveggel S, Williams P, Boven K; ECHO Study Group; THRIVE Study Group.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):33-42. doi: 10.1097/QAI.0b013e31824d006e.

PMID:
22343174
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk